CN102462772B - Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver - Google Patents
Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver Download PDFInfo
- Publication number
- CN102462772B CN102462772B CN201010543645.1A CN201010543645A CN102462772B CN 102462772 B CN102462772 B CN 102462772B CN 201010543645 A CN201010543645 A CN 201010543645A CN 102462772 B CN102462772 B CN 102462772B
- Authority
- CN
- China
- Prior art keywords
- liver
- fatty liver
- volume
- picrorhiza
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of an extract of total glucosides of picrorhiza in preparing medicines for preventing and/or treating fatty liver and other related diseases. A preparation method of the extract of total glucosides of picrorhiza comprises the following steps: extracting picrorhiza by using a C1-C5 fatty alcohol solution having a concentration of 0-95 (v/v), removing C1-C5 fatty alcohol from the extracting solution, and then filtering; letting the filtrate pass through macroporous adsorption resin, and eluting the filtrate by using a C1-C5 fatty alcohol solution having a concentration of 0-30 (v/v), and discarding the eluent; eluting by using a C1-C5 fatty alcohol solution having a concentration of 40-100 (v/v), and removing the solvent in the eluent. The extract of total glucosides of picrorhiza prepared by the invention can be prepared into medicines for preventing and/or treating alcoholic and non-alcoholic fatty liver, acute fatty liver or chronic fatty liver, and further can prevent the formation of hepatic fibrosis.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to a kind of purposes of picrorhiza rhizome total glycoside extract, be specifically related to a kind of picrorhiza rhizome total glycoside extract in the purposes for the preparation of preventing and/or treating in fatty liver medicine.
Background technology
Liver is lipometabolic vitals.Under normal circumstances, fat weight accounts for 3%～5% of liver gross weight, and the every 100g liver of normal person weight in wet base is containing 4～5g lipid, and wherein phospholipid accounts for more than 50%, and triglyceride accounts for 20%, and free fatty accounts for 20%, cholesterol approximately 7%, and all the other are cholesterol ester etc.When hepatocyte inner lipid is accumulated over 5% of liver weight in wet base, or be called fatty liver during the upper visible 1/3 above liver parenchyma fatization of per unit area of histology.The pathogenesis of fatty liver is not yet completely clear and definite so far, it is generally acknowledged that the imbalance between hepatocyte synthetic glycerine three esters and secretion low density lipoprotein, LDL is the main cause that forms fatty liver.
Fatty liver is the No.1 killer who destroys liver function, so far still for developed country's hepatopathys such as America and Europe disable and the dead primary cause of disease, also become first hepatopathy, patient is up to about 100,012,000, it is as a kind of global commonly encountered diseases, frequently-occurring disease, the serious harm mankind's physical and mental health and quality of life, and affect people and bring into play work efficiency.
The clinical emergency degree according to morbidity is divided into acute and chronic two large classes by fatty liver.Acute fatty liver sees drug intoxication, late trimester of pregnancy, Reye syndrome etc., and its clinical manifestation and prognosis are similar to acute or subacute severe viral hepatitis, if sequela is not generally stayed in treatment in time; The formation of chronic fatty liver is generally relevant with metabolism syndrome (diabetes, hyperlipemia and obesity etc.) with ethanol, therefore can be divided into alcoholic fatty liver and non-alcoholic fatty liver disease again.
Previously think that fatty liver is only benign lesion, makes slow progress or does not make progress.But research discovery in recent years, in alcohol fatty hepatopath, the sickness rate of fat hepatitis is approximately 40%, the sickness rate of fatty cirrhosis reaches more than 50%; In addition, 20% non-alcoholic fatty liver disease develops into fatty liver fibrosis, and then worsens as liver cirrhosis, and it is diseases related that wherein 30%～40% patient dies from these livers, and subacute liver failure and hepatocellular carcinoma occur part.
At present, there is no the specific medicament of special for treating fatty liver both at home and abroad, adopt fallen lipid drug and protects the liver the medication combined medication of class more clinically.Mostly these medicines are to work for the pathogeny of certain link of fatty liver or part, lack the specificity for the treatment of fatty liver.Although some lipid regulating agent has short term efficacy to fatty liver, affects liver function, make blood fat more concentrate on liver and carry out metabolism, increase burden of liver, long-term taking has potential liver toxicity, the state of an illness that on the contrary can weight fat liver.In view of lacking the specific medicament for the treatment of fatty liver, therefore from Chinese medicine, finding new fatty liver medicine has become one of focus of study of tcm new drug in recent years.
Chinese medicine Rhizoma Picrorhizae is the dry rhizome of Scrophulariaceae (Scrophulariaceae) Rhizoma Picrorhizae (Picrorhiza scrophulariiflora Pennell).The chemical research of Rhizoma Picrorhizae is found, Rhizoma Picrorhizae mainly contains iridoids, phenolic glycoside class, Aromatic acid constituents.Pharmacology and clinical research show, Rhizoma Picrorhizae take iridoids be main methods of glycosides have clear and definite protect the liver, anti-liver injury effect.In recent years research also shows, Picroside II Amphicoside 6-Vanilloylcatalpol can be by improving liver function, suppress lipid peroxidation, lowering the formation that TGF-β 1 and type i collagen mRNA and protein expression suppress hepatic fibrosis.
Summary of the invention
Therefore, the object of the invention is to provide based on Chinese medicine picrorhiza rhizome total glycoside extract a kind of newtype drug of effective treatment fatty liver.
As follows for realizing the technical scheme of above-mentioned purpose:
Picrorhiza rhizome total glycoside extract is in the purposes for the preparation of preventing and/or treating in fatty liver or its relevant disease medicine, and the preparation method of wherein said picrorhiza rhizome total glycoside extract comprises the following steps:
(1) take the C of concentration as 0～95% (volume/volume)
1-C
5fatty alcohol aqueous solution extracts Rhizoma Picrorhizae, removes the C in extracting solution
1-C
5after fatty alcohol, filter;
(2) filtrate is by macroporous adsorbent resin the C of concentration as 0～30% (volume/volume) of take
1-C
5fatty alcohol aqueous solution eluting, eluent discards;
(3) take the C of concentration as 40～100% (volume/volume)
1-C
5fatty alcohol aqueous solution eluting, removes the solvent in eluent.
In such use, preferably, the C adopting in step (1)
1-C
5the concentration of fatty alcohol aqueous solution is 0～30% (volume/volume).Preferably, the C adopting in step (2)
1-C
5fatty alcohol aqueous solution is 0～20% (volume/volume).Preferably, the C adopting in step (3)
1-C
5fatty alcohol aqueous solution is 40～60% (volume/volume).
In such use, macroporous adsorbent resin can be selected from one or more in styrene, divinylbenzene, acrylate and methacrylate type polarity or nonpolar macroporous adsorption resin.
In such use, the method for extraction can be selected from one or more in percolation, backflow and immersion, is preferably percolation.
In such use, by the gross weight of picrorhiza rhizome total glycoside extract, in described picrorhiza rhizome total glycoside extract, the content of Rhizoma Picrorhizae total glucosides is not less than 60% (w/w), the content of picroside Ⅱ is not less than 21% (w/w), and the content of picroside Ⅰ is not less than 13% (w/w).Preferably, described picrorhiza rhizome total glycoside extract also comprises picroside III, kutkin I V, 6-feruloyl catalpol and the different Resina Ferulae acyl of 6-catalpol.
In such use, medicine can be peroral dosage form or injection type.Peroral dosage form can be tablet, pill, capsule, granule or oral liquid.Injection type can be aqueous injection or injectable powder.
In such use, fatty liver can be alcoholic fatty liver or non-alcoholic fatty liver disease; Also can be acute fatty liver or chronic fatty liver.The relevant disease of fatty liver is specially the hepatic fibrosis that fatty liver causes.
In the picrorhiza rhizome total glycoside extract that the present invention finds to make through extracting method of the present invention after deliberation, Rhizoma Picrorhizae total glucosides content, up to more than 60% (w/w), is wherein rich in the effective ingredient such as iridoids.Adopt the research of acute and chronic fatty liver model to show, this picrorhiza rhizome total glycoside extract has liver heat removing fat, blood fat reducing, reduction transaminase, removing free radical, anti peroxidation of lipid, enhancing immunity, liver-protective effect.Therefore, the picrorhiza rhizome total glycoside extract of preparing with extracting method of the present invention can be made medicine, for preventing and/or treating, treats Alcoholic and non-alcoholic fatty liver disease, and acute fatty liver or chronic fatty liver, and then prevents the formation of hepatic fibrosis.
Compared with prior art, at least there is following beneficial effect in the present invention:
1, the present invention adopts water or low alcohol extraction, and adopt Amberlyst process to carry out purification, the composition of the total glycosides extractive obtaining and content are unlike the prior art, in picrorhiza rhizome total glycoside extract of the present invention, total glycosides content >=60% (w/w), picroside Ⅱ >=21% (w/w), picroside Ⅰ >=13% (w/w), in addition, also contain picroside III, kutkin I V, 6-feruloyl catalpol and the different Resina Ferulae acyl of 6-catalpol; Prior art is mainly picrorhiza iridoid total glycosides extractive, and wherein, picroside Ⅰ and picroside Ⅱ HPLC content amount to >=20% (w/w);
2, in fatty liver, the origin cause of formation of liver fat bulk deposition comprises that the output of liver fat output relative deficiency regulating liver-QI fat is definitely not enough.Liver fat output relative deficiency is that fatty acid increases or liver self synthetic fatty acid increases, accelerates due to the synthetic TG of liver, the chronic Models of Fatty Liver that in drug efficacy study, employing high lipid food brings out conventionally in entering the blood of liver; Compared with prior art, the present invention is except selecting above-mentioned model to carry out drug efficacy study picrorhiza rhizome total glycoside extract, and also for another origin cause of formation of fatty liver, i.e. liver fat output is definitely not enough, has designed acute fatty liver model and CCl that ethionine brings out
4fatty liver/the Liver Fibrosis Model of bringing out, has reflected respectively that liver VLDL is synthetic, paracrisis and fatty liver oxidation suppress.The multiple origin cause of formation according to pathogenesis of fatty liver, has designed several animal models, thus integrated survey the therapeutical effect of picrorhiza rhizome total glycoside extract to fatty liver.
3,, in the chmice acute Models of Fatty Liver that the present invention brings out at ethionine, continuous 3 gavages give picrorhiza rhizome total glycoside extract 15,30,60mg/kg; Other test dosages 20,40,80mg/kg, the onset dosage of the rat of picrorhiza rhizome total glycoside extract treatment fatty liver is 20mg/kg/ days, effective dosage ranges is 40～80mg/kg/ days.
Although have in 4 prior aries, Rhizoma Picrorhizae extract is used for the treatment of to the report with prevention of liver disease, but wherein the composition of Rhizoma Picrorhizae extract is different from the present invention with content, and because the kind of hepatopathy is a lot, the formation mechanism difference of different hepatopathys is very large, the hepatopathy that forms mechanism for difference needs specific aim to use different medicines, the present invention finds by large quantity research, and the Rhizoma Picrorhizae extract of specific composition prepared by the present invention has better effect in treatment fatty liver.
The specific embodiment
Below in conjunction with the specific embodiment, the present invention is further described in detail, the embodiment providing is only in order to illustrate the present invention, rather than in order to limit the scope of the invention.
Embodiment 1
20 kilograms of Rhizoma Picrorhizae pulverizing medicinal materials are become to coarse powder, with 60L water soaking 2 hours, pack percolator into, with water percolation, collect 240L percolate, be concentrated into the concentrated solution that is equivalent to 1g medical material/mL.By D101 macroporous adsorbent resin, with washing decontamination, again with 60% (volume/volume) ethanol water eluting, concentrate eluant, drying under reduced pressure makes 2.8 kilograms of picrorhiza rhizome total glycoside extracts, and wherein total glycosides content reaches 70% (w/w), picroside Ⅱ is 22.5% (w/w), picroside Ⅰ is 13.9% (w/w), in addition, also contains picroside III, picroside IV, 6-feruloyl catalpol and the different Resina Ferulae acyl of 6-catalpol.
Get 1.2 kilograms of above-mentioned picrorhiza rhizome total glycoside extracts, add 1.6 kilograms of starch, microcrystalline Cellulose 400g, granulates, encapsulated, and every containing total glycosides 30mg.
Embodiment 2
20 kilograms of Rhizoma Picrorhizae pulverizing medicinal materials are become to coarse powder, 30% (volume/volume) ethanol water with 60L soaks 12 hours, packs percolator into, with 30% (volume/volume) ethanol water percolation, collect 240L percolate, be concentrated into the concentrated solution that is equivalent to 1g medical material/mL.By AB-8 macroporous adsorbent resin, with washing decontamination, again with 50% (volume/volume) ethanol water eluting, concentrate eluant, drying under reduced pressure makes 2.6 kilograms of picrorhiza rhizome total glycoside extracts, and wherein total glycosides content reaches 75% (w/w), picroside Ⅱ is 22.8% (w/w), picroside Ⅰ is 14.6% (w/w), in addition, also contains picroside III, picroside IV, 6-feruloyl catalpol and the different Resina Ferulae acyl of 6-catalpol.
Get 1.1 kilograms of above-mentioned picrorhiza rhizome total glycoside extracts, add 1.6 kilograms of starch, microcrystalline Cellulose 400g, granulates, tabletting, and every containing total glycosides 30mg.
Embodiment 3
20 kilograms of Rhizoma Picrorhizae pulverizing medicinal materials are become to coarse powder, with 20% (volume/volume) ethanol water of 60L, reflux 3 times, each 2 hours, each 80L, merge extractive liquid,, is concentrated into the concentrated solution that is equivalent to 1g medical material/mL.By HPD100 macroporous adsorbent resin, with water and 20% (volume/volume) ethanol aqueous wash decontamination, again with 40% (volume/volume) ethanol water eluting, concentrate eluant, drying under reduced pressure makes 3 kilograms of picrorhiza rhizome total glycoside extracts, and wherein total glycosides content reaches 60% (w/w).Picroside Ⅱ is 21.6% (w/w), and picroside Ⅰ is 13.5% (w/w), in addition, also contains picroside III, picroside IV, 6-feruloyl catalpol and the different Resina Ferulae acyl of 6-catalpol.
Embodiment 4
20 kilograms of Rhizoma Picrorhizae pulverizing medicinal materials are become to coarse powder, with 10% (volume/volume) ethanol water of 240L, soak 24 hours, concentrating under reduced pressure soak, to 1g medical material/mL.By NKA macroporous adsorbent resin, with 10% (volume/volume) ethanol aqueous wash decontamination, again with 50% (volume/volume) ethanol water eluting, concentrate eluant, drying under reduced pressure makes 1 kilogram of picrorhiza rhizome total glycoside extract, wherein total glycosides content reaches 65% (w/w), picroside Ⅱ is 21.9% (w/w), picroside Ⅰ is 13.7% (w/w), in addition, also contain picroside III, picroside IV, 6-feruloyl catalpol and the different Resina Ferulae acyl of 6-catalpol.
Test example
The object of test is to verify the effect of picrorhiza rhizome total glycoside extract in preventing and/or treating fatty liver.In order to prove therapeutic effect and the safety of picrorhiza rhizome total glycoside extract of the present invention, its pharmacodynamics, pharmacology, toxicologic study process and result are as follows:
One, Pharmacodynamic test of active extract
1. the impact of acute fatty liver model ethionine being brought out
70 of ICR mices, male, body weight 20.3 ± 1.2 (18.2～22.5) g, is divided into 7 groups at random, 10 every group.Adopt ethionine to prepare acute fatty liver model, ethionine can suppress the synthetic apolipoprotein of liver, thereby make triglyceride in lipid metabolism (TG) transport liver, occurs obstacle, causes TG to accumulate in liver and forms fatty liver.After mice overnight fasting; except Normal group gavages distilled water; all the other each groups gavage DL-ethionine (250mg/kg; 20mL/kg) modeling; after 1h; Normal group and model control group gavage 0.5% (g/ml) CMC; be subject to reagent group to gavage the picrorhiza rhizome total glycoside extract of embodiment 1 preparation; dosage is respectively 15,30,60mg/kg/ time; positive drug group gavages respectively strong liver granule or tiopronin tablets; dosage is respectively 1700,100mg/kg/ time (be all equivalent to clinical consumption per day 3 times), administration volume is 10ml/kg.Administration every day 2 times, administration is 3 times altogether.After last administration, 1h puts to death mice, wins liver, takes lobus sinister edge 200mg, with 2ml acetone-alcohol mixeding liquid (volume ratio=1: 1) grind preparation homogenate, extracting lipid, centrifugal after, get colorimetric method for determining triglyceride (TG) for supernatant, T-CHOL (TC).Result is as shown in table 1.
The impact of table 1 picrorhiza rhizome total glycoside extract on liver TG, TC
Note: 1. with normal group comparison,
△ △p < 0.01,
△ △ △p < 0.001; With model group comparison,
*p < 0.05,
*p < 0.01.
Conclusion, in the chmice acute Models of Fatty Liver bringing out at ethionine, continuous 3 gavages give after picrorhiza rhizome total glycoside extract 15,30,60mg/kg treatment, liver TG be can significantly reduce, TG that liver raises declined respectively 15.7% (P > 0.05), 24.7% (P < 0.05), 29.6% (P < 0.01) made.Picrorhiza rhizome total glycoside extract 15mg/kg is suitable with the effect of strong liver granule 1700mg/kg; Picrorhiza rhizome total glycoside extract 30mg/kg and Kai Xi come the effect of 100mg/kg suitable.
2. the impact of chronic Models of Fatty Liver high lipid food being brought out
70 of SD rats, male, body weight 211 ± 5 (202～221) g.Except Normal group is fed normal diet, all the other rats high lipid food of feeding is prepared chronic Models of Fatty Liver.By the acid of a large amount of absorption ectogenous fat, the fatty acid that enters liver is increased, cause that the slow fat of hepatocyte becomes, finally form the Models of Fatty Liver similar to fatty liver due to clinical hyperlipoproteinemia.High lipid food formula is 5% (w/w) Adeps Sus domestica, 2% (w/w) cholesterol, 0.5% (w/w) cholate, 0.2% (w/w) methylthiouracil and 92.3% (w/w) normal diet.After moulding 8 weeks, animal pattern is divided into 6 groups at random, 10 every group.Start subsequently administration, Normal group and model control group gavage 0.5% (g/ml) CMC; Be subject to reagent group to gavage the picrorhiza rhizome total glycoside extract of embodiment 1 preparation, dosage is respectively 20,40,80mg/kg; Positive drug group respectively gavage gives strong liver granule or tiopronin tablets, and dosage is respectively 2300,140mg/kg (be all equivalent to clinical dosage 3 times), and administration volume is 5ml/kg.Administration every day 1 time, administration is 30 days altogether.
1h animal eye socket is got blood 1ml before administration and after last administration, prepares serum, measures serum triglycerides (TG), T-CHOL (TC), HDL-C (HDL-C), low-density lipoprotein cholesterol (LDL-C).Result is as shown in table 2 and table 3.
Put to death animal, win liver, take lobus sinister edge 200mg, with 2ml acetone-alcohol mixeding liquid (volume ratio=1: 1) grind preparation homogenate, extracting lipid, centrifugal after, get colorimetric method for determining TG, TC for supernatant.Result is as shown in table 4.
The impact of table 2 picrorhiza rhizome total glycoside extract on serum TG, TC
Note: 1. with normal group comparison,
△ △p < 0.01;
△ △ △p < 0.001; With model group comparison,
*p < 0.05;
*p < 0.01.
The impact of table 4 picrorhiza rhizome total glycoside extract on liver TG, TC
Note: 1. with normal group comparison,
△ △ △p < 0.001; With model group comparison,
*p < 0.05.
Conclusion: the chronic Models of Fatty Liver rat that the high lipid food of feeding brings out can effectively be removed the fat in liver and in blood in 30 days through picrorhiza rhizome total glycoside extract 20,40,80mg/kg treatment, the TG that liver is raise declined respectively 15.2% (P > 0.05), 37.8% (P < 0.05), 72.8% (P < 0.01); The TC's 21.7% (P > 0.05), 24.1% (P < 0.05), 24.8% (P < 0.05) that liver is raise has declined respectively; The TC's 45.3% (P > 0.05), 66.5% (P < 0.05), 77.1% (P < 0.01) that serum is raise has declined respectively; The LDL-C's 39.5% (P < 0.05), 55.4% (P < 0.01), 57.3% (P < 0.01) that serum is raise has declined respectively; The HDL-C/LDL-C's 0.7% (P > 0.05), 30.1% (P < 0.05), 30.8% (P < 0.01) that serum is declined has risen respectively; And can alleviate hepatic cell fattydegeneration degree.Picrorhiza rhizome total glycoside extract 40mg/kg is suitable with the effect of strong liver granule 2300mg/kg; The effect of picrorhiza rhizome total glycoside extract 40mg/kg and tiopronin tablets 140mg/kg is suitable.
3. the impact on ethanol+chronic Models of Fatty Liver that high fat brings out
70 of SD rats, male, body weight 212 ± 6 (200～223) g.Except Normal group gavages 0.5% (g/ml) CMC, all the other rats gavage moulding emulsion 15ml/kg every day, in order to manufacture the chronic Models of Fatty Liver similar to the mankind's dietary structure.Ethanol has liver toxicity, can suppress fatty acid beta-oxidation, and high fat can strengthen the damage of ethanol to liver.Moulding emulsion ratio is 60% (volume/volume) ethanol 10ml/kg, cholesterol 1g/kg, Adeps Sus domestica 5g/kg.After moulding the 8th week, animal pattern is divided into 6 groups at random, 10 every group.Start subsequently administration, Normal group and model control group gavage 0.5% (g/ml) CMC; Be subject to reagent group to gavage the picrorhiza rhizome total glycoside extract of embodiment 1 preparation, dosage is respectively 20,40,80mg/kg; Positive drug group respectively gavage gives strong liver granule or tiopronin tablets, and dosage is respectively 2300,140mg/kg (be all equivalent to clinical dosage 3 times), and administration volume is 5ml/kg.Administration every day 1 time, administration is 30 days altogether.
Before administration, animal eye socket is got blood 1ml, prepares serum, measures TG, TC.After last administration, 1h gets hematometry TG, TC, glutamic oxaloacetic transaminase, GOT (AST), glutamate pyruvate transaminase (ALT).Result is as shown in table 5 and table 6.
Put to death animal, win liver, take lobus sinister edge 200mg, with 2ml acetone-alcohol mixeding liquid (volume ratio=1: 1) grind preparation homogenate, extracting lipid, centrifugal after, get colorimetric method for determining TG, TC for supernatant.Result is as shown in table 7.Separately get hepatic tissue, with xanthine oxidase, measure SOD, with TBA method, measure MDA, with sample alkali hydrolysis method, measure hydroxyproline content.Result is as shown in table 8.
The impact of table 5 picrorhiza rhizome total glycoside extract on serum TG, TC
Note: 1. with normal group comparison,
△ △ △p < 0.001; With model group comparison,
*p < 0.05;
*p < 0.01;
* *p < 0.001.
The impact of table 6 picrorhiza rhizome total glycoside extract on Serum ALT, AST
Note: 1. with normal group comparison,
△p < 0.05;
△ △p < 0.01; With model group comparison,
*p < 0.05,
*p < 0.01.
The impact of table 7 picrorhiza rhizome total glycoside extract on liver TG, TC
Note: 1. with normal group comparison,
△ △ △p < 0.001; With model group comparison,
*p < 0.05,
*p < 0.01.
The impact of table 8 picrorhiza rhizome total glycoside extract on liver SOD, MDA
Note: 1. with normal group comparison,
△ △ △p < 0.01; With model group comparison,
*p < 0.05,
*p < 0.01.
Conclusion, the fat that the chronic Models of Fatty Liver rat that ethanol+high fat brings out can be removed in liver and in blood through picrorhiza rhizome total glycoside extract 20,40,80mg/kg treatment for 30 days, the TG that liver is raise declined respectively 13.3% (P > 0.05), 40.2% (P < 0.05), 76.1% (P < 0.01); The TC's 2.3% (P > 0.05,22.6% (P > 0.05), 60.5% (P < 0.05) that liver is raise has declined respectively; The TG's 79.2% (P < 0.05), 77.8% (P < 0.05), 93.1% (P < 0.01) that serum is raise has declined respectively; The TC's 47.7% (P > 0.05), 56.8% (P < 0.05), 81.2% (P < 0.05) that serum is raise has declined respectively; Can improve liver function, reduce transaminase, the ALT that serum is raise declined respectively 69.4% (P > 0.05), 77.6% (P < 0.05), 83.6% (P < 0.05); The AST's 82.9% (P < 0.05), 97.9% (P < 0.01), 95.7% (P < 0.01) that serum is raise has declined respectively; Improve SOD active, reduce MDA content.Picrorhiza rhizome total glycoside extract 20～40mg/kg is suitable with the effect of strong liver granule 2300mg/kg; The effect of picrorhiza rhizome total glycoside extract 40mg/kg and tiopronin tablets 140mg/kg is suitable.
4. couple CCl
4the impact of the fatty liver/Liver Fibrosis Model of bringing out
70 of SD rats, male, body weight 154 ± 10 (141～177) g.Except the neutral vegetable oil of Normal group cervical region subcutaneous injection, all the other rat skin lower injection 40% (volume/volume) CCl
4neutral vegetable oil solution.CCl
4in liver, through microsome cytochrome oxidase P450, activate as free radical CCl
3 -, cause the lipid peroxidation of hepatomicrosome, destroy liver cell mitochondria structure and function, it is reduced fatty oxidability, damage hepatocyte endoplasmic reticulum, makes the synthetic minimizing of lipoprotein.Injecting first dosage is 0.5ml/kg body weight, later 0.2ml/100g body weight, 2 times/week.After moulding 7 weeks, animal pattern is divided into 6 groups at random, 10 every group.Start subsequently administration, Normal group and model control group gavage 0.5% (g/ml) CMC; Tested medicine group gavages the picrorhiza rhizome total glycoside extract of being prepared by embodiment 1, and dosage is respectively 20,40,80mg/kg; Positive drug group respectively gavage gives strong liver granule or tiopronin tablets, and dosage is respectively 2300,140mg/kg (be all equivalent to clinical dosage 3 times), and administration volume is 5ml/kg.Administration every day 1 time, administration is 30 days altogether.
1h animal eye socket is got blood 1ml before administration and after last administration, prepares serum, measures serum glutamic oxalacetic transaminase (AST), glutamate pyruvate transaminase (ALT).Result is as shown in table 9.
Put to death animal, win liver, take lobus sinister edge 200mg, with 2ml acetone-alcohol mixeding liquid (volume ratio=1: 1) grind preparation homogenate, extracting lipid, centrifugal after, get colorimetric method for determining TG, TC for supernatant.Result is as shown in table 10.
Separately get hepatic tissue, with xanthine oxidase, measure superoxide dismutase (SOD), with TBA method, measure malonaldehyde (MDA), with sample alkali hydrolysis method, measure hydroxyproline content.Result is as shown in table 11.
Get again in 1cm * 1cm * 0.5cm right lobe of liver immersion formalin solution and fix, HE dyeing.Masson trichrome stain is observed rat liver collagen tissue (dyeing collagen fiber are blue) deposition and is waited variation.Collagen fiber area percentage=collagen fiber area/hepatic tissue area * 100%, result is as shown in table 12.
The impact of table 9 picrorhiza rhizome total glycoside extract on serum transaminase
Note: 1. with normal group comparison,
△ △ △p < 0.001; With model group comparison,
*p < 0.05;
*p < 0.01.
The impact of table 10 picrorhiza rhizome total glycoside extract on liver TG, TC
Note: 1. with normal group comparison,
△ △ △p < 0.001; With model group comparison,
*p < 0.05.
The impact of table 11 picrorhiza rhizome total glycoside extract on liver SOD, MDA
Note: 1. with normal group comparison,
△ △p < 0.01,
△ △ △p < 0.001; With model group comparison,
*p < 0.05,
*p < 0.01.
The impact of table 12 picrorhiza rhizome total glycoside extract on hepatic fibrosis
Note: 1. with normal group comparison,
△ △ △p < 0.01; With model group comparison,
*p < 0.05,
*p < 0.01.
Conclusion: CCl
4fatty liver/Liver Fibrosis Model rat of bringing out can be removed intrahepatic fat in 30 days through picrorhiza rhizome total glycoside extract 20,40,80mg/kg treatment, the TG that liver is raise declined respectively 7.0% (P > 0.05), 35.8% (P < 0.05), 38.5% (P < 0.05); Can improve liver function, reduce transaminase, the ALT that serum is raise declined respectively 14.0% (P > 0.05), 23.4% (P < 0.05), 42.0% (P < 0.01); The AST's 29.6% (P > 0.05), 47.0% (P < 0.05), 59.1% (P < 0.01) that serum is raise has declined respectively; And can improve SOD activity, reduce MDA content.Picrorhiza rhizome total glycoside extract 20～40mg/kg is suitable with the effect of strong liver granule 2300mg/kg; The effect of picrorhiza rhizome total glycoside extract 40～80mg/kg and tiopronin tablets 140mg/kg is suitable.
In sum, the onset dosage of the rat of picrorhiza rhizome total glycoside extract treatment fatty liver is 20mg/kg/ days, and effective dosage ranges is 40～80mg/kg/ days.Pharmacological action comprises the effects such as liver heat removing fat, blood fat reducing, reduction transaminase, anti peroxidation of lipid, removing free radical, the liver protecting, enhancing immunity, can effectively treat Alcoholic and non-alcoholic fatty liver disease by a plurality of links, prevents hepatic fibrosis.
Two, general pharmacological research
General pharmacological research is not found the overt toxicity of medicine to blood circulation and respiratory system.Also have no the impact on animal balance exercise ability, but collaborative with pentobarbital 30, under 270mg/kg dosage, sleep is had to certain promotion.
Three, acute toxicity test
After the picrorhiza rhizome total glycoside extract of mice single intravenous injection various dose, there is the at once of short duration signs of toxicity such as tic in medicine rear section animal, and the symptoms such as prostrate after medicine and movable minimizing all appear in each dosage group mice.Except lowest dose level group 0.70g/kg, all there is death in all the other each dosage treated animals, and increases with dosage, and dead animal was distributed in 1 hour, and asexuality difference.Dead and live and kill mice and cut open inspection organs and tissues and be showed no obvious abnormalities.After medicine, surviving animals 24h symptom disappears substantially, and toxic reaction degree and dosage are proportionate; Surviving animals body weight gain normal within the observation period after medicine.Mice single dose intravenous gives to have obvious toxic reaction after the picrorhiza rhizome total glycoside extract of doses, and causes animal dead, by Bliss method, calculates LD
50for 1.09g/kg (95% fiducial limit: 0.98g/kg～1.21g/kg).
After gastric infusion, 12.5g/kg dosage treated animal is after medicine in observation period of 14 days, the growth of animal average weight is starkly lower than concurrent control group (p < 0.05 or p < 0.01), and especially after medicine, in 1 week, body weight negative growth appears in indivedual animals; 10.0g/kg dosage treated animal is after medicine in observation period of 14 days, and body weight gain normal, with matched group relatively there are no significant difference (p > 0.05).Results suggest, it is maximal non-toxic amounts of reactants that mouse stomach gives 10.0g/kg.
Four, long term toxicity test
The continuous gavage of rat gives 50,150 and the picrorhiza rhizome total glycoside extract of 450mg/kg 6 months, within administration phase and convalescent period, observe animal general reaction, feed situation, measure the body weight of animal, administration 3 months, 6 months and 1 month convalescent period are detected the indexs such as hematological indices, blood parameters, system postmortem, organ coefficient and histopathology while finishing.Found that, high dose group, during administration, slow, the total bilirubin of body weight gain male and jenny slightly raises; In addition, the reticulocyte of high dose group jenny is slight rising and slight increase tendency appears in kidney organ coefficient, and except above-mentioned abnormal index, all the other every detection indexs are not all found the obvious change relevant to medicine.Middle dosage group, during administration, except the body weight gain of buck is slow, and the total bilirubin of jenny has outside slight rising, and all the other detect indexs and are showed no the significant change relevant to medicine.Low dose group, the every detection index of animal during administration is not all found the toxic reaction relevant to medicine.Drug withdrawal recovered after 1 month, and above-mentioned have the detection index of ANOMALOUS VARIATIONS all to recover normal.The main organs of histopathological examination has no organic disease and the delayed toxicity reaction relevant to medicine.Therefore, can think that rat oral gavage gives picrorhiza rhizome total glycoside extract 50mg/kg (being equivalent to clinical plan with 30 times of dosage), be basic security dosage.
Beasle dog continuous oral picrorhiza rhizome total glycoside extract 320mg/kg, 80mg/kg, 20mg/kg dosage, establish matched group, successive administration 180 days.After medicine, observe spirit, behavior, diet, the feces of animal every day, regularly carry out body weight, feces occult blood, urine biochemistry, electrocardiogram, hematology, blood biochemical, bone marrow, ophthalmology, pathological tissue etc. and check.Found that 320mg/kg, 80mg/kg dosage treated animal, at the initial slight gastrointestinal reaction (vomiting, loose stool) that occurs of administration, after administration, ERY inspection all has Some Animals to present the positive, but with administration process, does not increase the weight of; Histopathologic examination's mucous membrane of urinary bladder, gastrointestinal mucosa is slight congestion; 320mg/kg dosage treated animal glutamic oxaloacetic transaminase, GOT slightly raises; These variations can disappear after drug withdrawal.The spirit of 20mg/kg dosage treated animal, activity, diet, feces, body weight, anus temperature, hematology, blood biochemical, urine biochemistry, electrocardiogram all have no significant effect; This dosage is not for observing the dosage (calculate and be equivalent to intend 13 times of clinical dosage with every kg body weight, convert and be equivalent to intend 8.3 times of clinical dosage, 90mg/ people/sky, 60kg/ people with body surface area) of toxic reaction.
Claims (7)
1. a picrorhiza rhizome total glycoside extract is in the purposes for the preparation of preventing and/or treating in fatty liver or its relevant disease medicine, wherein, by the gross weight of described picrorhiza rhizome total glycoside extract, in described picrorhiza rhizome total glycoside extract, the content of Rhizoma Picrorhizae total glucosides is not less than 60%(w/w), the content of picroside Ⅱ is not less than 21%(w/w), the content of picroside Ⅰ is not less than 13%(w/w); The preparation method of described picrorhiza rhizome total glycoside extract comprises the following steps:
(1) take concentration as 10～30%(volume/volume) ethanol water extract Rhizoma Picrorhizae, the method for extraction is selected from one or more in percolation, backflow and immersion;
(2) concentrated extracting solution, concentrated solution is by macroporous adsorbent resin, with water and/or 10～20%(volume/volume) ethanol aqueous wash decontamination, eluent discards;
(3) take concentration as 40～50%(volume/volume) ethanol water eluting, concentrate eluant, drying under reduced pressure makes picrorhiza rhizome total glycoside extract.
2. purposes according to claim 1, is characterized in that, described macroporous adsorbent resin is selected from D101, AB-8, HPD100 or NKA.
3. purposes according to claim 2, is characterized in that, described macroporous adsorbent resin is AB-8.
4. according to the purposes described in any one in claims 1 to 3, it is characterized in that, described picrorhiza rhizome total glycoside extract also comprises picroside III, picroside IV, 6-feruloyl catalpol and the different Resina Ferulae acyl of 6-catalpol.
5. according to the purposes described in any one in claims 1 to 3, it is characterized in that, described medicine is peroral dosage form or injection type.
6. purposes according to claim 5, is characterized in that, described peroral dosage form is tablet, pill, capsule, granule or oral liquid; Described injection type is aqueous injection or injectable powder.
7. according to the purposes described in any one in claims 1 to 3, it is characterized in that, described fatty liver is acute fatty liver, and the relevant disease of described fatty liver is the hepatic fibrosis that fatty liver causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010543645.1A CN102462772B (en) | 2010-11-15 | 2010-11-15 | Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010543645.1A CN102462772B (en) | 2010-11-15 | 2010-11-15 | Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102462772A CN102462772A (en) | 2012-05-23 |
| CN102462772B true CN102462772B (en) | 2014-03-12 |
Family
ID=46067080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010543645.1A Active CN102462772B (en) | 2010-11-15 | 2010-11-15 | Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102462772B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105982998B (en) * | 2015-02-11 | 2019-03-05 | 天津药物研究院 | A kind of pharmaceutical composition and its preparation method and application for treating fatty liver |
| CN111000856A (en) * | 2020-01-03 | 2020-04-14 | 吉林大学 | Application of picroside II in preparing medicine for treating hyperlipemia |
| CN112168834A (en) * | 2020-10-12 | 2021-01-05 | 上海中医药大学 | Application of picroside I in preparation of medicine for preventing and treating hepatic fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457794A (en) * | 2002-05-15 | 2003-11-26 | 成都博瑞医药科技开发有限公司 | New use of picrorhiza rhizome and its iridoid glycoside extract |
| CN1488637A (en) * | 2003-09-05 | 2004-04-14 | 北京深文医药科技开发有限公司 | Method for preparing total aglycone extract of radix picrorrhizae |
-
2010
- 2010-11-15 CN CN201010543645.1A patent/CN102462772B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457794A (en) * | 2002-05-15 | 2003-11-26 | 成都博瑞医药科技开发有限公司 | New use of picrorhiza rhizome and its iridoid glycoside extract |
| CN1488637A (en) * | 2003-09-05 | 2004-04-14 | 北京深文医药科技开发有限公司 | Method for preparing total aglycone extract of radix picrorrhizae |
Non-Patent Citations (2)
| Title |
|---|
| 胡黄连提取物的含量测定及其肝保护作用;阎雪莹等;《中医药学报》;20090630;第37卷(第6期);第13-15页 * |
| 阎雪莹等.胡黄连提取物的含量测定及其肝保护作用.《中医药学报》.2009,第37卷(第6期),第13-15页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102462772A (en) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382798C (en) | Pharmaceutical composition containing caffeoylquinic acids | |
| Zhang et al. | Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat | |
| Ouassou et al. | Inhibition of α-glucosidase, intestinal glucose absorption, and antidiabetic properties by Caralluma europaea | |
| CN105560262A (en) | Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout | |
| CN102670864A (en) | Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes | |
| RU2736357C2 (en) | Composition of traditional chinese medicine for treating hypertension caused by atherosclerosis, and use thereof | |
| WO2012023146A1 (en) | A pharmaceutical composition of reformulated turmeric extract and a method thereof | |
| CN107157999A (en) | Application of the ligustrazine nitrone derivative in diabetes complicated disease is prevented and treated | |
| CN102462772B (en) | Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver | |
| CN106798762A (en) | One Plant Extracts and its preparation method and application | |
| CN100571708C (en) | A kind of have a synergistic pharmaceutical composition | |
| CN103479635A (en) | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| Mokiran et al. | Effect of dabai (Canarium odontophyllum) fruit extract on biochemical parameters of induced obese–diabetic rats | |
| RU2701567C1 (en) | Agent possessing hepatoprotective activity | |
| CN102151281B (en) | Flavonoid compound for preventing and treating diabetes and medicament application thereof | |
| Athraa | Impact of aqueous extract of Neem leaves in lowering blood glucose and lipid profile in stz induced diabetes mellitus mice | |
| US20110166226A1 (en) | Process for obtaining an extract rich in rosmarinic acid (ra) from the plant origanum vulgare and its use for the treatment of diabetes | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| KR100979459B1 (en) | Tetracera scandens extracts and 4H-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated L6 muscle cells | |
| CN101455753A (en) | Traditional Chinese medicine preparation capable of reducing fat | |
| CN105535152B (en) | Application of loquat leaf total sesquiterpene extract | |
| CN101411711B (en) | Composition containing alisol A and alisol A 24-acetic ester and use | |
| CN106822338A (en) | Compound of reducing blood sugar and blood fat, prevention and/or treatment diabetes and its complication and application thereof | |
| CN104324090B (en) | A kind of general rhubarb anthraquinone capsule composition | |
| CN103110680A (en) | Preparation method of total phenolic acid of erigeron breviscapus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin Patentee after: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. Address before: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120523 Assignee: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Assignor: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Contract record no.: X2020120000002 Denomination of invention: Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver Granted publication date: 20140312 License type: Exclusive License Record date: 20200203 |